ImmunoGen banks $20M up front in Lilly antibody-drug conjugate deal
This article was originally published in Scrip
Executive Summary
ImmunoGen racked up another multitarget deal involving its maytansinoid Targeted Antibody Payload (TAP) technology, this time with US drug powerhouse Lilly, which plans to use the technology to develop antibody-drug conjugate (ADC) anticancer therapeutics.
You may also be interested in...
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.